TY  - GEN 
AU  - Martín-Garcia, A.
AU  - López-Fernández, T.
AU  - Mitroi, C.
AU  - Chaparro-Muñoz, M.
AU  - Moliner, P.
AU  - Martin-Garcia, A. C.
AU  - Martínez Monzonís, Maria Amparo
AU  - Castro, A.
AU  - Lopez-Sendon, J. L.
AU  - Sanchez, P. L.
PY  - 2020
SN  - 2055-5822
UR  - http://hdl.handle.net/20.500.11940/16535
AB  - AIMS: Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction...
KW  - Ventricular Function
KW  - Drug Combinations
KW  - Middle Aged
KW  - Humans
KW  - Stroke Volume
KW  - Aminobutyrates
KW  - Retrospective Studies
KW  - Aged
KW  - Biphenyl Compounds
TI  - Effectiveness of sacubitril-valsartan in cancer patients with heart failure
DO  - 10.1002/ehf2.12627
KW  - CHUS
KW  - IDIS
VL  - 7
ER  -